News
LRMR
--
0.00%
--
Mid-Afternoon Market Update: Nasdaq Down 1%; Protagonist Therapeutics Shares Plummet
Toward the end of trading Friday, the Dow traded down 0.47% to 4,587.22 while the NASDAQ fell 1.05% to 15,023.11. The S&P also fell, dropping 0.85% to 4,435.65.
Benzinga · 1d ago
Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event
Larimar Therapeutics, Inc. ("Larimar") (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the SVB Leerink C...
GlobeNewswire · 2d ago
Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
BALA CYNWYD, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, Presi...
GlobeNewswire · 09/02 20:01
Opaleye Management Inc. Buys Kiniksa Pharmaceuticals, Larimar Therapeutics Inc, CM Life ...
GuruFocus News · 08/23 10:25
What You Need To Know About Larimar Therapeutics, Inc.'s (NASDAQ:LRMR) Investor Composition
The big shareholder groups in Larimar Therapeutics, Inc. ( NASDAQ:LRMR ) have power over the company. Institutions...
Simply Wall St. · 08/22 14:12
Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress
BALA CYNWYD, Pa., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that David Bettoun, PhD, Vice Pres...
GlobeNewswire · 08/19 11:00
77 Biggest Movers From Yesterday
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares surged 65.4% to close at $2.10 on Thursday after the company announced it is expanding its blockchain business to engage in cryptocurrency mining.
Benzinga · 08/13 09:14
Catalyst (CPRX) Up More Than 20% in Past 3 Months: Here's Why
Zacks.com · 08/11 16:48
Catalyst (CPRX) Q2 Earnings Top Estimates, Revenues Rise Y/Y
Zacks.com · 08/10 19:41
Reata (RETA) Stock Down Despite Q2 Earnings & Sales Beat
Zacks.com · 08/10 13:54
National Vision (EYE) to Report Q2 Earnings: What's in Store?
Zacks.com · 08/09 16:16
Why Larimar (LRMR) Might Surprise This Earnings Season
Zacks.com · 08/09 12:48
Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut
Zacks.com · 08/06 16:27
Fi3 FINANCIAL ADVISORS, LLC Buys iShares Core S&P 500 ETF, Vanguard FTSE Developed Markets ...
GuruFocus News · 08/04 20:38
Jazz Pharma (JAZZ) Q2 Earnings Beat, Sales Ride on GW Buyout
Zacks.com · 08/04 14:35
Larimar (LRMR) Upgraded to Buy: Here's Why
Zacks.com · 07/23 16:00
Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021
BALA CYNWYD, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, Presid...
GlobeNewswire · 07/08 20:01
61 Biggest Movers From Yesterday
Gainers BSQUARE Corporation (NASDAQ: BSQR) shares climbed 77.1% to close at $7.05 on Tuesday on abnormally-high volume. The company’s stock dropped around 10% on Friday.
Benzinga · 07/07 09:07
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Benzinga · 07/06 16:39
42 Stocks Moving In Tuesday's Mid-Day Session
Gainers Orbsat Corp. (NASDAQ: OSAT) shares jumped 74% to $9.47. BSQUARE Corporation (NASDAQ: BSQR) shares jumped 48.2% to $5.90 after dropping around 10% on Friday.
Benzinga · 07/06 16:00
Webull provides a variety of real-time LRMR stock news. You can receive the latest news about Larimar Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About LRMR
Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that is ineffective or no treatments available. Its cell penetrating peptide ( CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets that has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin ( FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in Phase I clinical program.